FDA Signals Potential for Standard Approval of Paxalisib in Glioblastoma
The FDA indicated paxalisib’s overall survival data could support standard approval in glioblastoma, as supported by GBM-AGILE study findings.
Related Articles
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a…
Nonsignificance Misinterpreted as an Effect’s Absence in Psychology: Prevalence and Temporal Analyses
Nonsignificant findings in psychological research are frequently misinterpreted as reflecting the effect’s absence. However, this issue’s exact prevalence remains unclear, as does whether this issue…
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment…
Novel Therapies and Combinations Lead the Way in Women’s Cancers in 2024
Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer.
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials – PubMed
SABR shows excellent long-term disease control for low- and intermediate-risk localized prostate cancer. Patients treated for prostate cancer have a moderate risk of SM, consistent…
Nontransplant Treatment for Relapsed Pediatric Hodgkin Lymphoma—Less Is More
Current up-front therapeutic approaches for classic Hodgkin lymphoma (cHL) in children and young adults aim to reduce treatment intensity to minimize long-term treatment-related morbidity. This…
Understaffed GP practices ‘not ready’ to take on more work from hospitals
Most GPs say their practice doesn’t have the staff to cope with government plans to shift more healthcare into the community, according to polling by…
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment…
Virtual Meetings | Research To Practice
Research To Practice (RTP) is pleased to offer these complimentary 1-hour CME/MOC-accredited virtual sessions. Each session will be moderated by Dr Neil Love and feature…
ESTRO/EANO recommendation on reirradiation of glioblastoma
Reirradiation of brain tumors has a long history of preclinical and clinical studies especially with regards to effectiveness and safety in the recurrent setting. Clinical…
